Stargardt Disease – Epidemiology – Mature Markets

Clarivate epidemiology’s coverage of Stargardt disease (STGD) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report both the diagnosed incidence and diagnosed prevalence in each country, as well as annualized case counts projected to the national population.

Clarivate Epidemiology’s STGD forecast will answer the following questions:

  • How will demographic trends, such as population aging, improving life expectancy, and population migration, affect the epidemiology of STGD over the 20-year forecast period?

All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

In addition to the total number of diagnosed prevalent cases for each forecast year, Clarivate epidemiology provides at least 10 years of forecast data for the following subpopulations:

  • Diagnosed incident cases.
  • Diagnosed incident cases by visual acuity in the worst eye.
  • Diagnosed prevalent cases by visual acuity in the worst eye.
  • … and many more (details available on request).

launch Related Market Assessment Reports